Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 13, 2020

View Archived Issues

In AML, collapse prevents relapse

Notable responses seen in COVID-19 patients with respiratory failure given RLF-100

Daiichi Sankyo describes new SIRT6 activators

G protein-coupled receptor 35 modulators discovered at Precision IBD

Novartis presents NLRP3 inflammasome inhibitors

Merck KGaA discovers dual adenosine A2A/A2B receptor antagonists

Discovery and preclinical evaluation of anticancer agent, PVHD-303

First-in-human data presented for [68Ga]P15-041 radiotracer

Yumanity Therapeutics identifies stearoyl-CoA desaturase 1/5 inhibitors

VBL announces second successful pre-planned interim analysis of the phase III OVAL study

First patient enrolled in phase III InPedILD study of nintedanib

FDA approves Viltepso for the treatment of DMD in patients amenable to exon 53 skipping therapy

First phase I study of ATG-017 approved in Australia

Recombinant SARS-CoV-2 S1-Fc fusion protein shows promise in animal species

Treadwell initiates phase II study of CFI-400945 and durvalumab in TNBC

TREM2 targeting can synergize with checkpoint blockade

Phase I study results support further evaluation of yellow fever monoclonal antibody TY-014

Bio-Path begins dosing in amended stage 2 of phase II prexigebersen study in AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...